Evidence map›Paper›PMID 28291820›Full record

ArticlePloS one2017

Gab3 overexpression in human glioma mediates Akt activation and tumor cell proliferation.

Pifeng Jia, Feng Li, Weiting Gu, Weifeng Zhang, Yu Cai

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Pifeng JiaDepartment of Neurosurgery, RuiJin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Feng LiDepartment of Neurosurgery, RuiJin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weiting GuDepartment of Neurosurgery, RuiJin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weifeng ZhangDepartment of Neurosurgery, RuiJin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu CaiDepartment of Neurosurgery, RuiJin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0002-1519-910X
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This current study tested expression and potential biological functions of Gab3 in human glioma. Gab3 mRNA and protein expression was significantly elevated in human glioma tissues and glioma cells. Its level was however low in normal brain tissues and primary human astrocytes. In both established (U251MG cell line) and primary human glioma cells, Gab3 knockdown by shRNA/siRNA significantly inhibited Akt activation and cell proliferation. Reversely, forced Gab3 overexpression in U251MG cells promoted Akt activation and cell proliferation. In vivo, the growth of U251MG tumors in nude mice was inhibited following expressing Gab3 shRNA. Akt activation in cancer tissues was also suppressed by Gab3 shRNA. Together, we conclude that Gab3 overexpression in human glioma mediates Akt activation and cancer cell proliferation.

Indexed as

Cell ProliferationAdaptor Proteins, Signal TransducingAnimalsBrain NeoplasmsEnzyme ActivationGene Knockdown TechniquesGliomaHeterograftsHumansMiceMice, NudeProto-Oncogene Proteins c-aktRNA InterferenceRNA, MessengerAdaptor Proteins, Signal TransducingGAB3 protein, humanProto-Oncogene Proteins c-aktRNA, Messenger

Identifiers

PMID28291820
PMCPMC5349442
OpenAlexW2670015776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.